An update from AgPlus Diagnostics CEO Fiona Marshall:
Well 2020 has been such an unusual year and suddenly it is only 5 weeks to Christmas. As we head towards the end of the year AgPlus is well positioned to deliver on the final stages of our Agilis™ PoC platform development as we finalise verification, with validation in early 2021.
We have made great strides at AgPlus in the last month. Testing has begun in earnest with our production cartridges on our prototype readers. This now allows us to encapsulate our electrochemistry assays into an enclosed 2 step system for rapid near patient testing. This is an exciting time for AgPlus and the first step to encompassing all three elements of our platform together on the road to commercialisation. We have also had the opportunity in the last months to start work on several new projects for clinical diagnostics with some new partners in the UK and Europe.
We have successfully secured another £1.1M of funding from our current investors in conjunction with Future Fund which keeps us on track for 2021 launch of the Agilis™ platform.
Testing of our COVID-19 antigen assay is underway and initial data show that we have good limits of detection. Our antibody assay development is complete with specificity > 99% and Sensitivity >98%. This assay has the capability to be used for monitoring immune responses to infection, post infection and post vaccination. If you are interested in talking with us regarding these assays please do get in touch. Dr Tito Bacarese-Hamilton one of our Scientific Board Advisors has written a extremely interesting white paper on the Role of Clinical diagnostics in management of SARS-COV2 and you can read this article here.
AgPlus is expanding our team and we welcome Ellie Marston as an apprentice in our production team. Look out for her Meet the Team piece next month.
Thank you for taking the time to read this month’s update, I hope you enjoyed it and please do let me know if you have any further question or would like to collaborate with AgPlus.